Visão geral da empresa
Alumis Inc. operates as a clinical stage biopharmaceutical entity dedicated to the development and commercialization of therapeutic medicines specifically targeting autoimmune disorders. The company functions within the broader healthcare sector, positioning itself in the specialized biotechnology industry where innovation in drug candidates is the primary driver of value creation. This organization maintains a workforce of 221 employees, supporting its extensive research and development initiatives for novel treatments. Its market capitalization stands at $2.89B, while annual revenue (TTM) reaches $24.05M, indicating a significant valuation relative to its current sales base. The disparity between the $2.89B market cap and the $24.05M revenue suggests that the market is pricing the company primarily on the potential future success of its pipeline assets, such as envudeucitinib, rather than on current operational profitability.
Saúde financeira
Alumis Inc. reported a revenue of $24.05M for the trailing twelve months, yet it recorded a net income of $-243,324,992 and an EBITDA of $-438,408,000. The substantial gap between the positive revenue figure and the massive negative net income reveals a cost structure dominated by high R&D expenditures and operational burn rates typical of early-stage biotechnology firms. The company generated a free cash flow of $-202,334,000, which indicates a consistent outflow of cash required to fund ongoing research, development, and commercialization activities before considering non-cash items. In terms of profitability metrics, the gross margin stands at 100.0%, reflecting the high-margin nature of selling proprietary drug candidates prior to significant commercial scaling or manufacturing costs. Conversely, the operating margin is -5067.1% and the profit margin is 0.0%, highlighting that operating expenses far exceed operating revenue, resulting in an overall loss on sales. The balance sheet shows $308.50M in cash against $36.91M in debt, providing a robust liquidity buffer, while the debt-to-equity ratio of 12.25 suggests a capital structure heavily weighted toward equity financing to avoid interest burdens. Despite the high debt-to-equity figure, the current ratio of 4.34 indicates strong short-term liquidity, as the company holds more than four times its current liabilities in current assets. Furthermore, the return on equity is -86.7% and the return on assets is -73.4%, demonstrating that management is currently utilizing shareholder capital and assets to generate losses rather than profits, a common characteristic during the clinical trial phases of drug development.
Avaliação de valorização
The trailing P/E ratio is N/A due to the lack of positive net income, whereas the forward P/E is -7.02, implying that the market anticipates continued negative earnings in the near future. The price-to-book ratio is 7.89, indicating that the market values the company at nearly eight times its book value, a significant premium likely driven by the intangible value of its drug pipeline and intellectual property. Alternative valuation metrics such as the price-to-sales ratio of 120.11 and an EV/EBITDA of -5.97 further illustrate that the stock is priced on revenue multiples rather than earnings power, which is standard for pre-commercial biotech assets. The stock has traded between a 52-week low of $2.76 and a 52-week high of $30.60, with the current price situated near the upper end of this historical range relative to the recent volatility. The beta value is N/A, meaning standard volatility metrics relative to the broader market are not calculated or available for this specific stock data set.
Growth & Income
The revenue growth (YoY) and earnings growth (YoY) are both listed as N/A, preventing a direct calculation of growth rates from the provided historical data points. Given that the net income and EBITDA are deeply negative, the company does not pay dividends, resulting in a dividend yield of N/A and a payout ratio of 0.0%. Consequently, Alumis Inc. reinvests its limited cash reserves and any potential future earnings directly into research and development efforts rather than distributing income to shareholders. The overall growth and income profile is characterized by a lack of current dividend income and undefined growth rates due to the absence of historical positive earnings data, relying instead on the potential for future commercialization of its drug candidates to generate returns.